Kornimate/medical-research-clean huggingface dataset:
music therapy intervention during kidney biopsy.

Conditions: Kidney Diseases; Kidney Dysfunction; Kidney Disease, Chronic

Summary: kidney biopsy (kb) is an invasive procedure that is very useful in diagnosing kidney disease in both the native kidney and the transplanted kidney. patients undergo kb can feel anxiety and pain. pain is considered one of the worst experiences for patients and anxiety affects the sympathetic nervous system, the endocrine system and the immune system. the aim of this preliminary study was to evaluate the influence of mti as a complementary/nonpharmacological intervention on heart rate variability, anxiety and pain and promote more compliant behaviours during kb.


Eligibility criteria:
inclusion criteria: * age over 18 years * not severe neurological or psychiatric conditions * not hearing impairment exclusion criteria: * age under 18 years * severe neurological or psychiatric conditions * hearing impairment

Keywords: music therapy anxiety pain heart rate variability satisfation
contribution of high resolution eeg functional connectivity measures to presurgical evaluation of patients with intractable epilepsy

Conditions: Epilepsy

Summary: electroencephalography (eeg) with very high spatial resolution (hr-eeg, 256 electrodes) allow for better analysis of local and global activity of the cerebral cortex, as compared with conventional eeg. since january 2012, the neurology department of chu rennes is the first clinical service in france equipped with such a system. applied to hr-eeg recordings, brain connectivity methods are likely to provide essential information (in the form of "connectivity graphs") on cortical networks, either dysfunctional or not, involved in the generation of interictal paroxysms (like spikes or spike-waves) and during seizures. so far, many methods have been proposed (see for a review: wendling et al., 2009; wendling et al., 2010). however, since each method is highly sensitive to the type of model that is assumed for the underlying relationship between distinct brain regions (ansari-asl et al., 2006), none of them has yet demonstrated its effectiveness.


Eligibility criteria:
inclusion criteria patients: * being more than 18 years old, * having a chronic partial epilepsy resistant to medical treatments well administered and well followed in the course of pre-surgical assessment. inclusion criteria healthy volunteers: * being french native speaker, * being more than 18 years old, * being right-handed. exclusion criteria patients: * all patients for whom a preoperative surgical exam is not suitable, * any patient with psychiatric disease or intellectual disorder such that informed consent could not be obtained, * any patient with no abnormal eeg during intercritical phases, * all patients presenting psychiatric, neuropsychological or developmental difficulties in addition to epilepsy, * adult persons subject to legal protection (judicial protection, temporary guardianship/guardianship, administrative supervision), persons deprived of their liberty and pregnant or lactating women. exclusion criteria healthy volunteers: * the presence of any psychiatric, neuropsychological, and developmental disorder, * any uncorrected visual impairment, * any trouble or delay in learning to read / speak or write french, * being fully bilingual or multilingual * medication, treatment and / or substances that may alter or modify brain functions, * adult persons subject to legal protection (judicial protection, temporary guardianship/guardianship, administrative supervision), persons deprived of their liberty and pregnant or lactating women.
sleep modulation to treat depression

Conditions: Major Depressive Disorder; Healthy

Summary: current first-line treatments for major depression (antidepressants and psychotherapy) show a long latency to response, and less than half of all patients experience full remission with optimized treatment, indicating the need for new developments. the aim of this study is to extend and further develop a longstanding line of research of using sleep neurophysiology as a 'window to the brain' and treatment development in major depression. particularly, this project is designed to test the feasibility, efficacy and mechanisms of action of a new sleep-based treatment technology.

the planned study is a single-centre, doubled-blind, randomized, sham controlled, repeated measures within-subject (stimulation and sham) study including patients with major depression and healthy controls, across four sleep laboratory nights (adaptation, baseline, stimulation and sham in counterbalanced order). the investigators will test the primary hypothesis that auditory-closed loop suppression of slow wave sleep will improve depressive clinical symptomatology compared to sham stimulation.

Eligibility criteria:
inclusion criteria: * written informed consent * mdd according to icd-10 criteria (f32.1/2, f33.1/2; i.e. unipolar depression) for patient group exclusion criteria: * relevant psychiatric disorders (other than mdd for the patient group), such as organic psychiatric disorders, lifetime history of substance dependency or current substance abuse (smoking will be allowed for recruitment reasons), schizophrenia or other psychotic disorders, affective disorders including bipolar disorder, borderline personality disorder, autism or other severe psychiatric disorders * known pregnancy * unstable medical conditions, such as unstable cardiovascular or metabolic disorders, etc. * relevant neurological disorders, including epilepsy, stroke, etc. * organic sleep disorders including relevant sleep apnea (ahi\>15/h), periodic limb movement disorder (plms index\>5/h), restless-legs-syndrome (rls), narcolepsy, circadian rhythm disorder or shift work/ jet lag * intake of medication affecting the central nervous system (other than antidepressants and lithium in patients); patients receiving benzodiazepines or (es)ketamine will not be included * current brain stimulation treatment, such as electroconvulsive therapy (ect), tms or deep brain stimulation * contraindications for tdcs or tms studies, including but not limited to metal in the head/ brain or epilepsy * hearing impairment or tinnitus (auditory stimulation study) * inability to follow the procedures of the study (for example due to language problems) * left-handedness
multi-centric study

Conditions: B ALL; CD22+ Expression; Refractory B-ALL

Summary: patients with relapsed/refractory adult acute lymphoblastic leukemia (all)have a very dismal prognosis. in this case, allogeneic transplantation is the only curative treatment when patient have obtained a second complete remission (cr. in france, in patients younger than 60 years old,the hypercvad regimen used by the mdanderson in houston is generally applied. in older patients (\>=60 years)or young patients \<= 60 years no eligible for intense chemotherapy, a combination of vincristine + dexamethasone is generally chosen in order to avoid too much toxicity but the result is worse in term of cr. more than 90% of all with a b phenotype (2/3 of cases in adults)express the surface antigen cd22 on leukemic blasts which thus represents an interesting target for therapy. epratuzumab is a humanized anti-cd22 antibody produced by immunomedics, inc, morris plain (new jersey, usa). epratuzumab has already shown efficacy in lymphoma patients. only one study, including 15 children, has been published so far reporting the efficacy and the toxicity of epratuzumab in the setting of all in monotherapy, one can observe 8 stable disease, 3 progressions and 4 partial responses. when combining chemotherapy and epratuzumab, 9cr were observed with acceptable toxicity. tolerance was acceptable. the french graall group proposes to test an age-adapted combination of chemotherapy + epratuzumab, in refractory/relapses cd22+ b all patients in order to improve their prognosis, in term of cr, survival and of number of patients eligible for allograft.


Eligibility criteria:
inclusion criteria: * age \>= 18 years * b-all (oms) with \>= 20 % of blasts in bone marrow * cd22+ expression \>= 30% of the blast population * refractory b-all defined by treatment failure after 2 successive courses of induction therapy or relapse \< 6 months after first cr * first relapse of b-all * second relapse or beyond * performance status 0-2 * creatinine clearance \>= 50 ml/min (cockroft formula) * serum bilirubine \<= 30 µmom/l * written informed consent exclusion criteria: * t-all * meningeal involvement * cd22 expression on tumor cells or \< 30% * hiv positive * active hepatitis b or c * left ventricular ejection fraction \< 50% in patients \<60 years * contra-indication to epratuzumab * previous or concurrent second malignancy except for adequately treated basal cell carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively treated solid cancer, with no evidence of disease for at least 5 years * any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * participation at the same time in another study in which investigational drugs are used * absence of written informed consent

Keywords: efficacy of chemo-immunotherapy
functional electrical stimulation on tibial nerve in stroke patients.

Conditions: Chronic Stroke

Summary: hemiparetic gait is one of the most common consequences after stroke. this impairment has a detrimental effects on the patients lies, limiting their social participation. previous studies have shown that there is a direct relationship between triceps surae activation and gait speed in stroke patients, that is, higher triceps surae muscle activation are correspond to greater gait speed. then, it can be hypothesized that therapies focused in strengthening the triceps surae also improves the patient gait. it has been shown that functional electrical stimulation (fes) can improve triceps surae activation when applied on healthy subjects. however, it has not been yet explored in chronic stroke patients. therefore, the aim of this study is to assess whether a fes program over tibial nerve contributes to the rehabilitation of the gait in chronic hemiparetic stroke patients. this study present a prospective interventional design, based on non-probabilistic sampling for convenience, and comprising a total of 15 volunteers with ischemic stroke of both genders and aged between 18 and 70 years old. volunteers will be recruited from hospitals and private rehabilitation centres, and must be currently engaged in a conventional rehabilitation program. the study will consist of twenty-four sessions, with a frequency of three sessions per week.


Eligibility criteria:
inclusion criteria: * age ranging between 18 to 70 years. * subjects with chronic ischemic stroke (more than 12 months of evolution) * ability to walk 20 mts. without third-party assistance. * hemiparesis with weakness and spasticity in the triceps surae. exclusion criteria: * previous injury on paretic lower limb * soft tissue or joint retraction limiting ankle range of motion (rom) * severe peripheral nervous system compromise * electronic devices that could be altered by the use of fes (e.g. cardiac pacemaker)

Keywords: functional electrical stimulation tibial nerve stimulation chronic stroke hemiparetic gait
benefits of post-pyloric feeding tubes in critically ill patients

Conditions: Critical Illness

Summary: the purpose of this study is to determine the benefit of feeding critically-ill patients beyond the stomach (post-pyloric). furthermore, because of the advent of two new post-pyloric feeding tubes (tiger 2 and syncro bluetube) designed to improve post-pyloric placement, the investigators will be evaluating the benefits of those two tubes as well.


Eligibility criteria:
inclusion criteria: * patients admitted to the icu who are deemed by the attending critical care physician to warrant tube feeds and expected to receive tube feeds for more than three days

Keywords: enteral feeds supplemental feeds transpyloric tube nasogastric tube
topical tranexamic acid after intravitreal injections

Conditions: Subconjunctival Hemorrhage

Summary: we aim to investigate whether topical administration of tranexamic acid can reduce the occurence of subconjunctival hemorrahge after routine intravitreal injections for retinal conditions.


Eligibility criteria:
inclusion criteria: subjects receiving intravitreal injections as part of their routine ophthalmological care exclusion criteria: pregnancy, oral contraceptives/hrt use, known systemic autoimmune disease, renal failure, active/suspected infection or inflammation in the treated eye, subconjunctival hemorrahge prior to inclusion, history of subarachnoid hemorrahge, thromboembolic events, increased risk for thromboembolic events, known sensitivity to the study drug
topical clobetasol for the treatment of toxic epidermal necrolysis

Conditions: Toxic Epidermal Necrolysis

Summary: the primary objectives of this study are to investigate the efficacy and safety of topical steroid ointment (clobetasol 0.05%) for the treatment of the cutaneous manifestations of toxic epidermal necrolysis (ten).

the experimental focus of this trial is thus to evaluate the safety and clinical outcomes of topical steroid (clobetasol 0.05% ointment) for treatment of the cutaneous manifestations of toxic epidermal necrolysis (ten). the design of the study is a randomized, placebo-controlled, double-blind split-body phase ii clinical trial in which clobetasol 0.05% or placebo ointment will be topically applied to opposite arms for a period of fourteen days. the primary endpoints of the study are to determine the time to cessation of skin detachment in both groups as well as the safety of topical clobetasol to treat the cutaneous manifestations of ten. secondary outcome measures will evaluate efficacy by comparing the time to re-epithelialization and the percentage of affected skin between the clobetasol and placebo arms at various time points. an additional aim of the study is to characterize the genes expressed during the ten disease state and any changes in gene expression following treatment with topical steroids, particularly those genes involved in the regulation of programmed cell death (apoptosis). this will be accomplished though molecular analysis of skin biopsy specimens obtained after treatment with clobetasol and placebo ointments. the specific hypothesis being tested is that two weeks of topical clobetasol will promote epidermal keratinocyte survival through suppression of tnf signaling, decreased granulysin expression and inhibition of other pro-apoptotic pathways resulting in shorter disease duration and decreased time to re-epithelialization. irb number: 642415-5

Eligibility criteria:
inclusion criteria: * characteristic histological findings on diagnostic biopsy * clinical diagnosis verified by two independent physicians * greater than 10% affected body surface area (bsa) * ability to start treatment within seven days or less from the onset of erosions * actively worsening disease (enlarging area of involvement or new erosions occurring over the last 24 hours) * patient body surface area (bsa) \> 1.0 m2 * reproductive age female patients must have a negative pregnancy test prior to enrollment exclusion criteria: * patients will be excluded if they are \ 85 years of age. * patients who have documented: * uncontrolled infection (e.g. documented bacteremia) * malignancy * known prior immunodeficiency * pregnancy * concurrent use of systemic corticosteroids in the burn center greater than or equal to 0.5 mg/kg/day of prednisone or equivalent dose of similar medication. * greater than 70% eroded skin * scoreten score \>3 on hospital admission * patients will also be excluded if they have: active hepatitis and/or an alt or ast greater than four times the normal limits, or renal insufficiency with an estimated gfr\<50 ml/min/1.73m2.
assessment of energetic resonance by cutaneous stimulation on withdrawal alcohol symptoms.

Conditions: Alcohol Withdrawal Syndrome

Summary: the purpose of resc study is to assess the efficacy of energetic resonance by cutaneous stimulation on alcohol withdrawal symptoms measured by cushman score and in a second time to measure the benzodiazepine amount prescribed during the withdrawal time.


Eligibility criteria:
inclusion criteria: * men and women between 18 and 80 years, * patient with alcohol addiction, * patient needing alcohol withdrawal in a hospital. * patient with social security, * patient with inform consent signed. exclusion criteria: * pregnant women * minor. * major with guardianship. * people without sufficient information because of troubles of cognitive functions, or without sufficient knowledge of french language.

Keywords: resc, alcohol withdrawal syndrome
efficacy of nepeta menthoides extract on anxiety of patients with depression: a double-blind randomized controlled clinical trial

Conditions: Depression; Anxiety

Summary: the aim of this study is to assess the efficacy of nepeta menthoides as an anti anxiety herbal remedy for depressed patients , in a 6 week randomized double-blind controlled trial. a total of 70 adult outpatients between 18-65 ages referring to psychiatry clinic of shiraz medical university, who having depression according to persian-language version of the beck depression inventory-second edition and get score above 11 according to persian version of beck anxiety inventory (bai) and diagnosis is confirmed by at two psychiatrists are randomly allocated into two groups and assign to receive 400 mg of freeze dried powder of nepeta menthoides or 50 mg of sertraline in the uniformed capsules twice daily (in the morning and 1-2 hours before sleeping time at night). exclusion criteria were pregnancy and lactation, allergy to n. menthoides and lamiaceae family, patients with suicidal thoughts or previous suicidal attempt, patients with unstable cardiac, renal and hepatic diseases, seizure and hypothyroidism and patients who used substances or alcohol and patients who had indication for electroconvulsive therapy.. severity of anxiety (by persian version of beck anxiety inventory (bai)) and also common possible side effects of drugs will assess in baseline, 2nd week, 4th week and then two weeks after the end of the intervention (in 6th week)


Eligibility criteria:
inclusion criteria: 1. having depression according to persian-language version of the beck depression inventory-second edition 2. get score above 7 according to persian version of beck anxiety inventory (bai) exclusion criteria: 1. pregnancy and lactation 2. allergy to n. menthoides and lamiaceae family 3. patients with suicidal thoughts or previous suicidal attempt 4. patients with unstable cardiac, renal and hepatic diseases, seizure and hypothyroidism 5. patients who used substances or alcohol 6. patients who had indication for electroconvulsive therapy -
a study to assess change in disease activity in adolescents and adults with moderate to severe prurigo-type atopic dermatitis in japan who are treated with oral upadacitinib

Conditions: Atopic Dermatitis

Summary: atopic dermatitis (ad) is a skin condition that may cause a rash and itching due to inflammation of the skin. around one-third of patients with ad have had at least 1 incidence of prurigo nodularis (pn), which is characterized by intense, persistent itchy skin and sometimes pain with burning. in this study, the effectiveness of upadacitinib (upa) will be assessed in participants with prurigo-type ad in a real world (rw) setting in japan. upa is an approved drug for the treatment of ad. adults and adolescents who have been diagnosed with prurigo-type ad and prescribed upa according to the label and practice in japan will be enrolled in this observational study. the doctor's decision to prescribe upa will be made prior to and independently of study participation. approximately 200 participants will be enrolled in the study at 10 sites in japan. participants will receive extended-release oral tablets of upa once-daily for 48 weeks. there will be no additional burden for participants in this trial compared to their standard of care. participants will attend regular visits during the course of the study at a hospital or clinic.


Eligibility criteria:
inclusion criteria: * physician confirmed diagnosis of moderate to severe atopic dermatitis (ad) at baseline * ad symptom onset \> 1 year prior to baseline * initiation of upa treatment for ad is indicated and prescribed per the label in japan * worst pruritus numerical rating scale (wp-nrs) ≥ 4 at baseline * presence of palpable prurigo nodules at baseline exclusion criteria: * prior treatment with upa * contraindications to upa * chronic pruritus resulting from another condition (e.g., neuropathic disorders) than ad, prurigo nodularis (pn) * pn caused by medication, metal allergy, infection, insect bite * current participation in interventional research

Keywords: prurigo nodularis prurigo-type ad skin dermatology upadacitinib admire rinvoq
a prospective study on predictive value of non-invasive atherosclerotic measurements in elderly chinese

Conditions: Atherosclerosis; Cardiovascular Disease

Summary: the purpose of this study is to determine whether non-invasive atherosclerotic measurements (bapwv, imt, fmd, cacs, abi) are valuable predictors for cardiovascular events in elderly. at inception, routine physical examination and non-invasive atherosclerotic measurements will conducted on all participants. then they will be followed prospectively for at least 2 years. all cardiovascular and other health events will be recorded.

cardiovascular disease is the most common cause of morbidity and mortality in the world, especially in elderly. conventional risk factors are widely used in clinical practice, but it is inadequate and inaccurate due to no direct evaluation of artery. however, invasive method, it is difficult to be applied in atherosclerosis screening and only used in advanced institutions, is expensive and unacceptable. we are trying to assess the value of noninvasive measurements in predicting cardiovascular events. five invasive methods will be applied in the study, including * brachial-ankle pulse wave velocity(bapwv) * carotid intimal-medial thickness(cimt) * flow mediated dilation(fmd) * ankle-brachial index(abi) * coronary artery calcification score(cacs) these indices represent not only different phase of atherosclerosis, but also various sections and arterial layers.

Eligibility criteria:
inclusion criteria: * chinese, age\>=60, no gender restriction. * to be able to apply the measurement mentioned above. * medical history are maintained precisely. * tianjin medical university general hospital is the participants' designated hospital by national health authority. exclusion criteria: * systemic inflammation. * malignant tumor * chronic lung disease * liver disease * aortic aneurysm

Keywords: atherosclerosis prognosis flow-mediated dilatation brachial-ankle pulse wave velocity carotid intimal-medial thickness coronary artery calcification score ankle-brachial index